Opinion|Videos|August 30, 2024
Biomarkers as Tools in Management of Type 2 Inflammation
Author(s)Reynold A. Panettieri Jr, MD
An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
Advertisement
Episodes in this series
- What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
- How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?
Advertisement
Related to this article
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Lean MASLD shows milder histology than overweight and obese MASLD but similar mortality and event risk, with fibrosis tied to prognosis.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5